James L Januzzi1, Sunil Suchindran2, Udo Hoffmann3, Manesh R Patel4, Maros Ferencik5, Adrian Coles6, Jean-Claude Tardif7, Geoffrey S Ginsburg8, Pamela S Douglas4. 1. Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org. 2. Duke Center for Applied Genomics and Precision Medicine, Durham, North Carolina. 3. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 4. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 5. Oregon Health and Science University, Portland, Oregon. 6. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 7. Montreal Heart Institute, Université de Montréal, Montreal, Canada. 8. Duke Center for Applied Genomics and Precision Medicine, Durham, North Carolina; Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Abstract
BACKGROUND: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. OBJECTIVES: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. METHODS: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. RESULTS: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. CONCLUSIONS: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
BACKGROUND: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. OBJECTIVES: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. METHODS:Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. RESULTS: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. CONCLUSIONS: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
Authors: Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams Journal: J Am Coll Cardiol Date: 2012-11-19 Impact factor: 24.094
Authors: Alon Eisen; Marc P Bonaca; Petr Jarolim; Benjamin M Scirica; Harvey D White; Michal Tendera; Mikael Dellborg; Jose C Nicolau; Joao Morais; Keith A A Fox; Erin A Bohula; Sabina A Murphy; Eugene Braunwald; David A Morrow Journal: Clin Chem Date: 2016-11-08 Impact factor: 8.327
Authors: Marc P Bonaca; Ryan G O'Malley; Petr Jarolim; Benjamin M Scirica; Sabina A Murphy; Michael J Conrad; Christopher P Cannon; Harvey D White; Eugene Braunwald; David A Morrow; Marc S Sabatine Journal: J Am Coll Cardiol Date: 2016-07-19 Impact factor: 24.094
Authors: Paul Welsh; David Preiss; Anoop S V Shah; David McAllister; Andrew Briggs; Charles Boachie; Alex McConnachie; Caroline Hayward; Sandosh Padmanabhan; Claire Welsh; Mark Woodward; Archie Campbell; David Porteous; Nicholas L Mills; Naveed Sattar Journal: Clin Chem Date: 2018-08-20 Impact factor: 8.327
Authors: Pamela S Douglas; Udo Hoffmann; Kerry L Lee; Daniel B Mark; Hussein R Al-Khalidi; Kevin Anstrom; Rowena J Dolor; Andrzej Kosinski; Mitchell W Krucoff; Daniel W Mudrick; Manesh R Patel; Michael H Picard; James E Udelson; Eric J Velazquez; Lawton Cooper Journal: Am Heart J Date: 2014-03-18 Impact factor: 4.749
Authors: Brendan M Everett; Maria Mori Brooks; Helen E A Vlachos; Bernard R Chaitman; Robert L Frye; Deepak L Bhatt Journal: N Engl J Med Date: 2015-08-13 Impact factor: 91.245
Authors: Maros Ferencik; Thomas Mayrhofer; Michael T Lu; Daniel O Bittner; Hamed Emami; Stefan B Puchner; Nandini M Meyersohn; Alexander V Ivanov; Elizabeth C Adami; Deepak Voora; Geoffrey S Ginsburg; James L Januzzi; Pamela S Douglas; Udo Hoffmann Journal: JACC Cardiovasc Imaging Date: 2022-05-11
Authors: Yuen-Kwun Wong; Chloe Y Y Cheung; Clara S Tang; JoJo S H Hai; Chi-Ho Lee; Kui-Kai Lau; Ka-Wing Au; Bernard M Y Cheung; Pak-Chung Sham; Aimin Xu; Karen S L Lam; Hung-Fat Tse Journal: Cardiovasc Diabetol Date: 2019-12-17 Impact factor: 9.951
Authors: Ahmed AlBadri; Janet Wei; Odayme Quesada; Puja K Mehta; Yi Xiao; Yi-An Ko; R David Anderson; John Petersen; Babak Azarbal; Bruce Samuels; Timothy D Henry; Galen Cook-Wiens; Eileen M Handberg; Jennifer Van Eyk; Carl J Pepine; C Noel Bairey Merz Journal: Arterioscler Thromb Vasc Biol Date: 2020-10-08 Impact factor: 10.514